The trial evidence for a mortality benefit comes from large-scale meta-analyses of randomized controlled trials, and the two largest disagree. A 2023 systematic review and meta-analysis of 80 RCTs encompassing over 163,000 participants found that vitamin D supplementation was associated with a statistically significant reduction in all-cause mortality (OR: 0.95, 95% CI 0.91–0.99). An earlier 2019 meta-analysis of 52 trials with 75,454 participants found no association with all-cause mortality (RR 0.98, 95% CI 0.95–1.02); its one significant mortality finding was a 16% lower risk of cancer death. The benefit appears most pronounced when correcting pre-existing deficiency, supplementation in already-replete individuals shows weaker effects. Animal research in C. elegans models shows vitamin D3 directly extends lifespan and improves healthspan through protein homeostasis pathways involving genes SKN-1, IRE-1, and XBP-1, suggesting mechanistic plausibility beyond observational data.
Vitamin D’s role in bone metabolism is the best-established benefit. It increases intestinal calcium absorption from approximately 10–15% (when deficient) to 30–40% (when sufficient), directly enabling bone mineralization. Deficiency causes rickets in children and osteomalacia in adults, conditions of impaired bone mineralization. In older adults, adequate vitamin D status is associated with reduced fracture risk and slower bone density loss. Supplementation trials consistently show reduced fracture rates in populations with baseline deficiency, though supplementation without confirmed deficiency shows more modest effects.
Vitamin D receptors are present on virtually all immune cells, and active vitamin D (1,25-dihydroxyvitamin D) directly modulates both innate and adaptive immune responses. It enhances the pathogen-killing capacity of macrophages, regulates T-cell differentiation, and promotes immune tolerance to reduce autoimmune activity. Examine’s vitamin D page, which aggregates 107 trials and 38 meta-analyses covering over 1.27 million participants, lists improved immune health among the benefits associated with supplemental vitamin D and attributes vitamin D’s antibacterial effects to its action on immune cells and its promotion of genes encoding antimicrobial peptides. Upper respiratory tract infection is the most-covered condition in that database, though the page does not display a grade for it. Low vitamin D levels are consistently associated with higher incidence and severity of respiratory infections, with supplementation studies showing meaningful protective effects particularly in deficient individuals.
A systematic review and meta-analysis of 14 observational studies with over 31,000 participants found significantly lower vitamin D levels in people with depression compared to controls (SMD 0.60), with the lowest versus highest vitamin D categories carrying higher depression risk (cross-sectional OR 1.31; cohort HR 2.21). While this association does not establish causation, and the mechanism is not fully characterized, vitamin D receptors are present throughout the brain, including areas regulating mood such as the prefrontal cortex, hippocampus, and hypothalamus. The meta-analysis authors call for randomized trials to determine whether the association is causal, and Examine’s overview notes that while vitamin D is often taken for depression, the evidence on whether supplementation improves these outcomes is mixed. Routine supplementation for mood benefit in replete individuals lacks robust RCT support.
A 2025 RCT from the VITAL trial (1,054 participants, 4 years, double-blind placebo-controlled) found that 2,000 IU/day of vitamin D3 significantly reduced telomere attrition by 0.14 kilobase pairs over four years compared to placebo. Telomeres are protective caps at the ends of chromosomes that shorten with age; their rate of attrition is a validated biomarker of cellular aging and disease risk. Comparing that figure against a cohort in which telomeres shortened roughly 460 base pairs over a decade, the authors suggest the 140 base pairs preserved could mean a 3-year decrease in aging, an inference drawn from outside the trial rather than a measured outcome. Notably, omega-3 supplementation in the same trial showed no significant effect on telomere length, suggesting this is a vitamin D-specific mechanism. Animal model research in C. elegans shows vitamin D3 engaging longevity-associated genes SKN-1, IRE-1, and XBP-1 to promote protein homeostasis and extend lifespan; that work concerns protein insolubility rather than telomere maintenance, so it is not a mechanism for this trial’s result.
The commonly recommended supplementation dose for most adults is 1,000–2,000 IU per day, with higher doses (up to 4,000 IU/day) used to correct confirmed deficiency under physician guidance. The daily upper tolerable limit is typically set at 4,000 IU/day for long-term use. Vitamin D is fat-soluble, so it should be taken with a meal containing fat for optimal absorption. Testing 25(OH)D blood levels is the most reliable way to confirm status, with sufficiency generally defined as 30–50 ng/mL. People with dark skin, limited sun exposure, or aged 65 and older are at elevated risk for deficiency and most likely to benefit from supplementation.